Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 12, 2009, Pages 5800-5804

  Yang, Hongwei ^a,b   Hirooka, Kazuyuki ^a   Fukuda, Kouki ^a   Shiraga, Fumio ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CANDESARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; NEUROPROTECTIVE AGENT; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GLAUCOMA; IMMUNOHISTOCHEMISTRY; INTRAOCULAR PRESSURE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; RETINA; RETINA BLOOD VESSEL; RETINA GANGLION CELL; ANIMAL; CHRONIC DISEASE; DISEASE MODEL; DRUG EFFECT; ENZYME IMMUNOASSAY; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; UPREGULATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; CELL SURVIVAL; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; FEMALE; GLAUCOMA; IMMUNOENZYME TECHNIQUES; INTRAOCULAR PRESSURE; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RETINAL GANGLION CELLS; TETRAZOLES; UP-REGULATION;

EID: 73349132037     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3678     Document Type: Article

References (38)

1. Brubaker RF. Delayed functional loss in glaucoma: LII Edward Jackson Memorial Lecture. Am J Ophthalmol. 1996;121:473-483.
2. Osborne NN, Chidlow G, Nash MS, Wood JP. The potential of neuroprotection in glaucoma treatment. Curr Opin Ophthalmol. 1999;10:82-92.
3. Chierzi S, Fawcett JW. Regeneration in the mammalian optic nerve. Restor Neurol Neurosci. 2001;19:109-118.
4. Danser AH, Derkx FH, Admiraal PJ, Deinum J, de Jong PT, Schale-kamp MA. Angiotensin levels in the eye. Invest Ophthalmol Vis Sci. 1994;35:1008-1018.
5. Deschepper CF, Mellon SH, Cumin F, Baxter JD, Ganong WF. Analysis by immunocytochemistry and in situ hybridization of retina and its mRNA in kidney, testis, adrenal, and pituitary of the rat. Proc Natl Acad Sci USA. 1986;83:7552-7556.
6. Derkx FH, Alberda AT, Zeilmaker GH, Schalekamp MA. High concentrations of immunoreactive renin, protein and enzymatically-active renin in human ovarian follicular fluid. Br J Obstet Gynaecol. 1987;94:4-9.
7. Sramek SJ, Wallow IH, Tewksbury DA, Brandt CR, Poulsen GL. An ocular renin-angiotensin system; immunohistochemistry of angio-tensinogen. Invest Ophthalmol Vis Sci. 1992;33:1627-1632.
8. Wagner J, Jan Danser AH, Derkx FH, et al. Demonstration of renin mRNA, angiotensin mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br J Ophthalmol. 1996;80:159-163.
9. Savaskan E, Löffler KU, Meier F, Müller-Spahn F, Flammer J, Meyer P. Immunohistochemical localization of angiotensin-converting enzyme, angiotensin II and AT1 receptor in human ocular tissue. Ophthalmic Res. 2004;36:312-320.
10. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology, XXIII: the angiotensin II receptors. Pharmacol Rev. 2000;52:415-472.
11. Murphy TJ, Alexander RW, Griendling KK, Runge MS. Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature. 1991;351:233-236.
12. Dai WJ, Funk A, Herdegen T, Unger T, Culman J. Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke. 1999;30:2391-2398.
13. Nishimura Y, Ito T, Saavedra JM. Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke. 2000;31: 2478-2486.
14. Yamakawa H, Jezova M, Ando A, Saavedra JM. Normalization of endothelial and inducible nitric oxide synthase expression in brain microvessels of spontaneously hypertensive rats by angiotensin II AT1 receptor inhibition. J Cereb Blood Flow Metab. 2003;23:371-380.
15. Ando H, Zhou J, Macova M, Imboden H, Saavedra JM. Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke. 2004;35:1726-1731.
16. Zhou J, Ando H, Macova M, Dou J, Saavedra JM. Angiotensin II AT1 receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats. J Cereb Blood Flow Metab. 2005;25:878-886.
17. Nagai N, Noda K, Urano T, et al. Selective suppression of pathologic, but not physiologic, retinal neovascularization by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci. 2005;46:1078-1084.
18. Downie LE, Pianta MJ, Vingrys AJ, Wilkinson-Berka JL, Fletcher EL. AT1 receptor inhibition prevents astrocyte degeneration and restores vascular growth in oxygen-induced retinopathy. Glia. 2008; 56:1076-1090.
19. Hirooka K, Baba T, Fujimura T, Shiraga F. Prevention of visual field defect progression with angiotensin-converting enzyme inhibitor in eyes with normal-tension glaucoma. Am J Ophthalmol. 2006; 142:523-525.
20. Hasizume K, Mashima Y, Fumayama, et al. Genetic polymorphisms in the angiotensin II receptor gene and their association with open-angle glaucoma in a Japanese population. Invest Ophthalmol Vis Sci. 2005;46:1993-2001.
21. Sawada A, Neufeld AH. Confirmation of the rat model of chronic, moderately elevated intraocular pressure. Exp Eye Res. 1999;69: 525-531.
22. Neufeld AH, Sawada A, Becker B. Inhibition of nitric-oxide syn-thase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc Natl Acad Sci USA. 1999;96:9944-9948.
23. Lu Q, Zhu Y, Wong PT. Neuroprotective effects of candesartan against cerebral ischemia in spontaneously hypertensive rats. Neu-roreport. 2005;16:1963-1967.
24. Costagliola C, Verolino M, de Rosa ML, Iaccarino G, Ciancaglini M, Mastropasqua L. Effect of oral losartan potassium administration on intraocular pressure in normotensive and glaucomatous human subjects. Exp Eye Res. 2000;71:167-171.
25. Laquis S, Chaudhary P, Sharma SC. The patterns of retinal ganglion cell death in hypertensive eyes. Brain Res. 1998;784:100-104.
26. Ausinsch B, Munson ES, Levy NS. Intraocular pressure in children with glaucoma during halothane anesthesia. Am J Ophthalmol. 1977;9:1391-1394.
27. Hetherington J, Shaffer RN. Tonometry and tonography in congenital glaucoma. Invest Ophthalmol. 1968;7:134-137.
28. Pease ME, Hammond JC, Quigley HA. Manometric calibration and comparison of TonoLab and TonoPen tonometers in rats with experimental glaucoma and in normal mice. J Glaucoma. 2006; 15:512-519.
29. Ohashi M, Aihara M, Saeki T, Araie M. Efficacy of TonoLab in detecting physiological and pharmacological changes in rat intraocular pressure: comparison of TonoPen and microneedle ma-nometry. Jpn J Ophthalmol. 2008;52:399-403.
30. Moore CC, Milne T, Morrison JC. Noninvasive measurement of rat intraocular pressure with the Tono-Pen. Invest Ophthalmol Vis Sci. 1993;34:363-369.
31. Saupe KW, Sobol SC, Koh SG, Apstein CS. Effect of AT1 receptor block begun late in life on normal cardiac aging in rats. J Cardio-vasc Phalmacol. 2003;42:573-580.
32. Kurihara T, Ozawa Y, Shinoda K, et al. Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation. Invest Ophthalmol Vis Sci. 2006;47:5545-5552.
33. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494-501.
34. Zalba G, San Josè G, Moreno MU, et al. Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension. 2001;38: 1395-1399.
35. Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol. 2000;1:120-129.
36. Garcia-Valenzuela E, Shareef S, Walsh J, Sharma SC. Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp Eye Res. 1995;61:33-44.
37. McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, et al. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci. 2002;43:1077-1087.
38. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363:1711-1720.